November 2022
·
39 Reads
·
9 Citations
This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.
November 2022
·
39 Reads
·
9 Citations
August 2022
·
24 Reads
·
2 Citations
AIDS and Behavior
Using the incidence of bacterial sexually transmitted infection (STI) as a surrogate for condomless sexual behavior, we assessed the association between STI and uncontrolled HIV replication among in-care persons with HIV (PWH) enrolled in a longitudinal HIV cohort study in the District of Columbia (the DC Cohort). Although STI occurrence initially correlated with higher HIV viral load (VL), this difference became more attenuated over time (2012–2016). This was true overall and among those with the greatest number of STIs [age 18–34, men who have sex with men (MSM)]. This likely reflects gains in population-wide virologic control through improved antiretroviral therapy and access to care, which helps mitigate the risk of HIV transmission.
April 2022
·
7 Reads
The Lancet
March 2022
·
37 Reads
·
1 Citation
AIDS Research and Human Retroviruses
This study explored virological outcomes of two-drug (2DRs) and three-drug (3DRs) antiretroviral regimens in adults with HIV in the DC Cohort. We analyzed 310 treatment-experienced adults with sustained HIV RNA ≤50 copies/mL at baseline, 53 of whom switched to 2DRs and 257 continued 3DRs. Adults on 2DRs and 3DRs had similar demographics (median age 53.3 years, 76.8% cisgender male, 76.1% Black). Adults on 2DRs had more participants with ≥2 comorbidities (62.3% vs. 42.8%, p = .019), had a longer time since HIV diagnosis (median years 20.4 vs. 13.2, p = .017), and received the regimen of interest for a shorter duration (median years 1.3 vs. 3.3, p < .001) compared with adults on 3DRs. Adults receiving 2DRs had a higher, although nonsignificant, risk for virological failure (two consecutive HIV RNA ≥50 copies/mL) at 24 months follow-up than adults on 3DRs (6.7% vs. 1.7%, respectively; p = .10). Future analysis of the effectiveness of 2DRs is needed.
November 2021
·
45 Reads
·
5 Citations
June 2021
·
122 Reads
·
43 Citations
Paul De Lay and co-authors introduce a Collection on the design of targets for ending the AIDS epidemic.
November 2020
·
388 Reads
·
82 Citations
The Lancet HIV
In light of the increasing global burden of new HIV infections, growing financial requirements, and shifting funding landscape, the global health community must accelerate the development and delivery of an HIV cure to complement existing prevention modalities. An effective curative intervention could prevent new infections, overcome the limitations of antiretroviral treatment, combat stigma and discrimination, and provide a sustainable financial solution for pandemic control. We propose steps to plan for an HIV cure now, including defining a target product profile and establishing the HIV Cure Africa Acceleration Partnership (HCAAP), a multidisciplinary public-private partnership that will catalyse and promote HIV cure research through diverse stakeholder engagement. HCAAP will convene stakeholders, including people living with HIV, at an early stage to accelerate the design, social acceptability, and rapid adoption of HIV-cure products.
October 2020
·
166 Reads
·
58 Citations
The Lancet
May 2020
·
151 Reads
·
14 Citations
December 2019
·
166 Reads
·
55 Citations
The Lancet
... 26 Investment in research and development has accelerated vaccine creation and improved HIV treatments. 27 Integration of health services has enhanced resilience, while a focus on preparedness ensures readiness for future health emergencies. These lessons aim to improve global health outcomes and create robust systems capable of addressing complex public health challenges. ...
November 2022
... Their perspectives, experiences, and needs can provide valuable insights and contribute to more effective research and product development strategies. In doing so, it will be important to ensure that an HIV vaccine is developed and integrated into existing and future effective prevention strategies [37]. ...
November 2021
... The study's prediction for the AIDS incidence in Shandong Province from 2023 to 2030 reveals an increasing trend, with an expected incidence of 6.33 in 2030. Despite the United Nations Sustainable Development Goals aiming to end the AIDS epidemic by 2030 25 . the prediction suggests that AIDS in Shandong Province continues to exhibit an increasing trend, highlighting a significant gap from the 2030 target. ...
June 2021
... Additionally, research indicates that a scenario such as PIC is more likely than complete HIV elimination 7,8,10,[31][32][33][34][35][36][37] . This implies that PHIV and key populations will not have a choice between PIC or HIV elimination as a new treatment option. ...
November 2020
The Lancet HIV
... countries (UK and South Africa), highlighting the need for additional high-quality experimental studies in PLWH. This is particularly important for SARS-CoV-2 vaccines based on adenovirus type-5 (Ad5) platforms, given prior concerns associated with higher risk of HIV acquisition in participants of Ad5 vectored HIV-1 vaccine trials [10]. Although follow-up data from one of these studies did not find increased risk of HIV progression among participants who became HIV-infected, it remains critical to monitor the effects of other Ad-5-based vaccines on HIV infection and progression [11]. ...
October 2020
The Lancet
... Similar poor awareness results have been reported in other countries. [19][20][21] In response, various governments have taken steps, such as observance of HIV vaccine awareness day on May 18. [22] However, there is a need to create further awareness through various social media platforms, tele advertisements, and national policies. ...
May 2020
... Recent estimates indicate that 4 million lives could have been saved if an effective antiviral had been available within 6 months of the start of the pandemic 5 . Moreover, although effective SARS-CoV-2 vaccines were quickly developed, this is not always possible for all viruses, as is the case of HIV-1 6 . Even for SARS-CoV-2, it has taken years for COVID -19 vaccines to reach 20 % of the population in low-income nations 7 . ...
December 2019
The Lancet
... [12][13][14][15] As such, both federal and local ending the HIV epidemic (EHE) efforts are increasingly turning to implementation science to accelerate and support intervention uptake and dissemination in the field. [16][17][18][19][20][21] Implementation strategies are the building blocks of effective implementation; they refer to specific methods and techniques designed to enhance adoption, administration, and sustainment of interventions in practice. 22,23 The implementation science field has developed a collection of 73 specific implementation strategies, called the Expert Recommendations for Implementing Change (ERIC) compendium, 24 which have been grouped into 9 thematic clusters. ...
December 2019
JAIDS Journal of Acquired Immune Deficiency Syndromes
... In recent years, the concept of "Undetectable = Untransmittable" (U = U) has emerged as a transformative framework for understanding outcomes. The U = U principle asserts that PLWHA who receive ART and maintain an undetectable viral load-defined as fewer than 200 copies/mL-for at least 6 months cannot sexually transmit the virus to others (Cohen et al., 2016;Eisinger et al., 2019). This concept, supported by robust scientific evidence, has significantly shaped global HIV treatment and prevention strategies (Bavinton et al., 2018;Rodger et al., 2019;Phanuphak et al., 2020). ...
January 2019
JAMA The Journal of the American Medical Association
... [17][18][19][20][21][22][23][24] The US government including the NIH, the Centers for Disease Control, and Health Resources and Services Administration have thus invested significantly in recent years in efforts to End the HIV Epidemic in the United States through implementation science and scaling of evidence-based practice. 9,[25][26][27] Funding for IR both in the United States and internationally has been steadily increasing in recent years. 1 There is often a lengthy delay in evidence generation, although some of this may be field specific. 11,12,[28][29][30] The objective of these analyses was to review the scientific production process and time to dissemination of HIVrelated IR findings. ...
August 2018
Annals of Internal Medicine